Zasocitinib is also being evaluated in a head-to-head study against Bristol Myers Squibb’s Sotyktu (deucravacitinib) in ...

Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, ...

One of the biggest names in pharma is rolling out a new direct-to-consumer (DTC) campaign during the biggest night in music. Airing before a national audience totaling in the millions during the ...

Guselkumab has received approval for moderate to severe plaque psoriasis in children and adolescents from the age of 6 years who are candidates for systemic therapy.1The decision is supported by the ...

Although some people with plaque psoriasis can control their symptoms by using topical treatments that are applied to the skin, some people with moderate or severe plaque psoriasis do not get enough ...

Otezla is the first oral therapy approved for moderate to severe plaque psoriasis in this patient population. The Food and Drug Administration (FDA) has expanded the approval of Otezla ® (apremilast) ...

Appoints accomplished commercial leader Chris Martin to its Board of DirectorsMENLO PARK, Calif., Dec. 11, 2025 (GLOBE ...

A topical therapy, PF-07038124 0.01%, administered once daily was more effective than the vehicle control in patients with atopic dermatitis (AD) and plaque psoriasis, a study finds. The topical ...

Amgen announces new FDA-approved oral treatment option for children and adolescents with moderate to severe plaque psoriasis. Amgen has announced the availability of apremilast (Otezla) in the United ...